Database : HANSEN
Search on : TALIDOMIDA/ANALOG [Subject descriptor]
References found : 3 [refine]
Displaying: 1 .. 3   in format [Detailed]

page 1 de 1

  1 / 3 HANSEN  
              next record last record
select
to print
Id:13938
Author:Dredge, Keith; Marriott, J. Blake; Dalgleish, Angus G
Title:Immunological effects of thalidomide and its chemical and functional analogs ..-
Source:s.l; s.n; 2002. 13 p. ilus, tab.
Abstract:Thalidomide has recently shown considerable promise in the treatment of a number of conditions, such as leprosy and cancer. Its effectiveness in the clinic has been ascribed to wide-ranging properties, including anti-TNF-alpha, T-cell costimulatory and antiangiogenic activity. Novel compounds with improved immunomodulatory activity and side effect profiles are also being evaluated. These include selective cytokine inhibitory drugs (SelCIDs), with greatly improved TNF-alpha inhibitory activity, and immunomodulatory drugs (IMiDs) that are structural analogs of thalidomide, with improved properties. A third group recently identified within the SelCID group, with phosphodiesterase type 4-independent activity, is in the process of being characterized in laboratory studies. This review describes the emerging immunological properties of thalidomide, from a historical context to present-day clinical applications, most notably in multiple myeloma but also in other cancers, inflammatory disease, and HIV. We also describe the laboratory studies that have led to the characterization and development of SelCIDs and IMiDs into potentially clinically relevant drugs. Early trial data suggest that these novel immunomodulatory compounds may supercede thalidomide to become established therapies, particularly in certain cancers. Further evidence is required, however, to correlate the clinical efficacy of these compounds with their known immunomodulatory, antiangiogenic, and antitumor properties. (AU).
Descriptors:TALIDOMIDA/analog
TALIDOMIDA/imunol
TALIDOMIDA/farmacol
SISTEMA IMUNE/ef drogas
NEOPLASIAS/quimioter
NEOPLASIAS/imunol
INFECCOES POR HIV/quimioter
INFECCOES POR HIV/imunol
ADJUVANTES IMUNOLOGICOS/farmacol
INIBIDORES DE ANGIOGÊNESE/imunol
INIBIDORES DE ANGIOGÊNESE/farmacol
ANTIVIRAIS/imunol
ANTIVIRAIS/farmacol
Limits:HUMANO
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 04731/s


  2 / 3 HANSEN  
              first record previous record next record last record
select
to print
Id:12226
Author:Sampaio, E. P; Hernandez, M. O; Carvalho, D. S; Sarno, E. N
Title:Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro ..-
Source:s.l; s.n; 2002. 7 p. ilus, graf.
Descriptors:APOPTOSE
CITOCINAS
CITOCINAS
ERITEMA NODOSO
IMUNOSSUPRESSORES
IMUNOSSUPRESSORES
INTERLEUCINA-12
MONOCITOS
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
RNA MENSAGEIRO
RNA MENSAGEIRO
RNA MENSAGEIRO
TALIDOMIDA
TALIDOMIDA
TALIDOMIDA
FATOR DE NECROSE TUMORAL/AI/GE
Location:BR191.1; 08709/s


  3 / 3 HANSEN  
              first record previous record
select
to print
Id:11287
Author:Marriott, J. Blake; Muller, George; Dalgleish, Angus G
Title:Thalidomide as an emerging immunotherapeutic agent ..-
Source:s.l; s.n; 1999. 3 p. .
Descriptors:ANORMALIDADES INDUZIDAS POR DROGAS
SINDROME DE IMUNODEFICIENCIA ADQUIRIDA
ADJUVANTES IMUNOLOGICOS
ANTIINFLAMATORIOS NAO ESTEROIDES
ANTIINFLAMATORIOS NAO ESTEROIDES
DESENHO DE DROGAS
ERITEMA NODOSO
ERITEMA NODOSO
IMUNOTERAPIA
HANSENIASE LEPROMATOSA
NEOPLASIAS
NEOVASCULARIZAÇAO PATOLOGICA
CÉLULAS TH2
CÉLULAS TH2
TALIDOMIDA
TALIDOMIDA
TALIDOMIDA
FATOR DE NECROSE DE TUMOR
Location:BR191.1; 07226/s



page 1 de 1
   


Refine the search
  Database : HANSEN Advanced form   
Search for : Free form   

    Search in field  
1  
2
3
 
           



Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO
Latin American and Caribbean Center on Health Sciences Information